Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC
Sponsor: National Cancer Institute (NCI)
Terminated
Premature closure - investigator left the National Institutes of Health.
Other terminated trials from National Cancer Institute (NCI)
Other Carcinoma, Non-Small-Cell Lung trials with similar outcome
Listed as NCT00923273, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .